Currently, PD-L1 is considered a rough biomarker for the therapeutic prediction of PD-1 blockade, and promising markers such as TMB or tumor-infiltrating lymphocytes fail to identify the progression to ICI treatment. The gene discussed is CD274; the disease is neoplasm.